Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma
- 13 June 2019
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 144 (1) , 107-115
Abstract
Immunodeficiency is a major risk factor for primary central nervous system lymphoma (PCNSL), but data on the disease in immunocompromised hosts are scarce. We aimed to define clinical and imaging features and determine prognostic factors for immunodeficiency-associated PCNSL.Keywords
This publication has 38 references indexed in Scilit:
- CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014Neuro-Oncology, 2017
- Diagnosis and management of primary central nervous system lymphomaCancer, 2017
- Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapyNeurology, 2017
- Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern EraAmerican Journal of Transplantation, 2013
- Primary central nervous system post‐transplantation lymphoproliferative disorderCancer, 2010
- Epstein Barr Virus-Associated Primary CNS Lymphomas in Elderly Patients on Immunosuppressive MedicationsJournal of Neuropathology & Experimental Neurology, 2008
- Immunodeficiency-associated lymphomasBlood Reviews, 2008
- EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetilNeuro-Oncology, 2007
- Primary CNS lymphomaNature Clinical Practice Neurology, 2007
- AIDS-related lymphoproliferative diseaseBlood, 2006